share_log

SciSparc | CORRESP: CORRESP

SciSparc | CORRESP: CORRESP

SciSparc | CORRESP:信函
美股SEC公告 ·  2024/06/18 00:42

Moomoo AI 已提取核心信息

SciSparc Ltd., a biotechnology company, has submitted Post-Effective Amendment No. 2 to its Registration Statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) on June 17, 2024. This submission is in response to the SEC's comment letter dated May 16, 2024, regarding the company's initial Post-Effective Amendment No. 1 filed on May 2, 2024. SciSparc has addressed the SEC's comments by revising its prospectus to clarify whether the combined entity, following its merger with AutoMax, will continue the business of SciSparc, AutoMax, or both. Additionally, the company has updated the 'Use of Proceeds' section to specify how the proceeds from the SEPA will be utilized, whether for SciSparc's or AutoMax's operations. SciSparc has also provided a comprehensive discussion of AutoMax's business operations as requested by the SEC. The company acknowledges its responsibility for the accuracy and adequacy of its disclosures.
SciSparc Ltd., a biotechnology company, has submitted Post-Effective Amendment No. 2 to its Registration Statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) on June 17, 2024. This submission is in response to the SEC's comment letter dated May 16, 2024, regarding the company's initial Post-Effective Amendment No. 1 filed on May 2, 2024. SciSparc has addressed the SEC's comments by revising its prospectus to clarify whether the combined entity, following its merger with AutoMax, will continue the business of SciSparc, AutoMax, or both. Additionally, the company has updated the 'Use of Proceeds' section to specify how the proceeds from the SEPA will be utilized, whether for SciSparc's or AutoMax's operations. SciSparc has also provided a comprehensive discussion of AutoMax's business operations as requested by the SEC. The company acknowledges its responsibility for the accuracy and adequacy of its disclosures.
生物技术公司SciSparc Ltd.于2024年6月17日向美国证券交易所(SEC)提交了《F-1表格》注册声明的第二个生效修改版。此次提交是针对SEC 2024年5月16日的评论信函而进行的,该评论信函涉及公司于2024年5月2日提交的首个生效修改版No.1。SciSparc已经通过修订招股说明书澄清了在与AutoMax合并后的联合实体是否将继续SciSparc、AutoMax或两者的业务,以回应SEC的评论。此外,该公司已更新‘募集资金用途’部分,以明确SEPA所募集资金的使用范围,是用于SciSparc还是用于AutoMax的业务。SciSparc还按SEC的要求提供了对AutoMax业务运营的全面讨论。该公司认识到其披露的准确性和充分性的责任。
生物技术公司SciSparc Ltd.于2024年6月17日向美国证券交易所(SEC)提交了《F-1表格》注册声明的第二个生效修改版。此次提交是针对SEC 2024年5月16日的评论信函而进行的,该评论信函涉及公司于2024年5月2日提交的首个生效修改版No.1。SciSparc已经通过修订招股说明书澄清了在与AutoMax合并后的联合实体是否将继续SciSparc、AutoMax或两者的业务,以回应SEC的评论。此外,该公司已更新‘募集资金用途’部分,以明确SEPA所募集资金的使用范围,是用于SciSparc还是用于AutoMax的业务。SciSparc还按SEC的要求提供了对AutoMax业务运营的全面讨论。该公司认识到其披露的准确性和充分性的责任。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息